Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and …
Biotech News | BioPharma Dive
4 days ago · The latest biotech news for biopharmaceutical professionals
Pharma News | BioPharma Dive
Dec 9, 2025 · The latest pharma news for biotech and biopharmaceutical professionals
Deep Dive - BioPharma Dive
Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a digital divide between highly resourced health systems and safety-net providers ...
10 clinical trials to watch the rest of 2025 | BioPharma Dive
Jan 2, 2025 · 10 clinical trials to watch the rest of 2025 Expected readouts in obesity, lung cancer and atopic dermatitis headline a series of study results that could give the biotechnology sector a boost in …
The biopharma industry outlook on 2025: Uncertainty and change
Jan 24, 2025 · The biopharma industry outlook on 2025: Uncertainty and change The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as …
Clinical Trial News | BioPharma Dive
5 days ago · The latest clinical trial news for biotech and biopharmaceutical professionals
Gene Therapy News | BioPharma Dive
Dec 4, 2025 · The latest gene therapy news for biotech and biopharmaceutical professionals
What will 2025 hold for biopharma? | BioPharma Dive
Jan 21, 2025 · Will 2025 herald a sudden turnaround for biopharma? Unlikely, but continued recovery is likely with some strong growth in therapy areas including cancer, diabetes and – inevitably – obesity. …
Biotech's M&A outlook is uncertain. Track the deals ... - BioPharma Dive
Sobi is paying $950 million upfront, and potentially $550 million more, for startup Arthrosi Therapeutics, which has an experimental gout drug in Phase 3 testing.